<DOC>
	<DOCNO>NCT02752672</DOCNO>
	<brief_summary>Dithranol ( know U.S.A. anthralin Germany cignolin ) one old safe topical anti-psoriatic treatment . However , despite explorative investigation , skin disease-clearing mechanism dithranol remain poorly understood ( Painsi et al , JDDG 2015 ) . The purpose study investigate therapeutic mechanism dithranol psoriasis .</brief_summary>
	<brief_title>Study Therapeutic Mechanisms Dithranol Treatment Patients With Chronic Plaque Psoriasis</brief_title>
	<detailed_description>Skins biopsy psoriatic skin blood sample take ( day 0 ) several time point start ( day 4 , week 2-3 , week 6-7 ) dithranol therapy subject explorative analysis ( see outcome measure ) . A total maximal 15 psoriasis patient enrol . Normal lesion-adjacent skin 10 patient undergoing surgery non-inflammatory condition serve control .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Anthralin</mesh_term>
	<criteria>Males females 18 year age Clinical diagnosis chronic plaque psoriasis Dithranol treatment schedule Systemic antipsoriatic therapy ( DMARD , phototherapy and/or Biologics ) within 4 week study entry ( start dithranol treatment ) Topical treatment steroid vitamin D3 analogue within 2 week study entry ( start dithranol treatment ) Autoimmune disorder Poor general health status Intolerance dithranol Pregnancy lactation period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>dithranol</keyword>
	<keyword>therapeutic mechanism</keyword>
</DOC>